Partnership Opportunities

Treatments for ADHD

Treatments for deficit hyperactivity disorder (ADHD) and related problems through personalized medicine and improved diagnosis

Technology Overview

Attention Deficit Hyperactivity Disorder (ADHD) is a very common problem, affecting 6 to 10% of children. Children with ADHD often have concomitant psychiatric, medical and learning problems, and if untreated, teens with ADHD have a higher chance of school failure and dropout, substance or alcohol abuse and delinquency. Interventions, both through medication use and behavior conditioning therapy, have high proven efficacy in treating ADHD and associated mood disorders in children.

Dr. Mark SteinDr. Mark Stein

Dr. Stein, past president of the American Professional Society for ADHD and Related Disorders, is an internationally recognized leader in ADHD treatment and through the lifespan. His group has overseen many clinical trials where their multi-disciplinary diagnostic approaches have been used as the gold standard against which the FDA establishes efficacy for novel ADHD assessment methods. This has placed Dr. Stein and his team in an excellent position to help manage upcoming clinical trials at every stage of development (phase I-IV).

Ongoing work conducted by Dr. Stein’s group has focused significantly on personalized treatment regimens for ADHD and other neurobehavioral disorders. Two of the initiatives overseen by Dr. Stein that have shown great efficacy are the Program to Evaluate/Enhance Attention, Regulation & Learning (PEARL) clinic, and a summer treatment program called Camp Sea STAR. Both of these initiatives emphasize high levels of direct and personalized therapy to help build social and organizational skills, and have shown significant behavioral improvements in patients over relatively short timeframes. Dr. Stein also conducts research focused on precision medication. This includes the identification of clinical and genetic biomarkers that can guide the selection of the most effective treatment options for individual patients. Dr. Stein also has expertise in the measurement of sleep and activity level, and is interested in developing new interventions targeting sedentary activity and other impairments associated with ADHD. His team is also working on a telehealth platform to treat multiplex ADHD families, and continuing studies on the relationship between ADHD and sleep problems and genomic predictors of response to ADHD treatment.

Dr. Stein is interested in industry partnerships that leverage his vast experience in ADHD evaluation, including development of mobile apps designed for use in assessing outcomes for clinical trials and for improving treatment adherence. Furthermore, Dr. Stein is interested in developing commercial treatment programs for ADHD (e.g., summer treatment programs, tutor-based treatment programs), training opportunities for industry partners, and research to identify biomarkers that will facilitate personalized treatment of ADHD, as well as clinical trial management and consultation.

Stage of Development

  • Clinical: Phase I-IV

Partnering Opportunities

  • Collaborative research opportunity
  • Sponsored research agreement
  • Consultation agreement
  • Software/app development


  1. Russell D, Weiss, M, and Stein M., A Maximum Dose for Methylphenidate: How much is too much? JAMA Pediatrics (2019)
  2. Steingard R, Connor D, Taskarin  S, Markowitz J, Stein M., New Formulations of Stimulants: An Update for Clinicians. Journal of Child and Adolescent Psychopharmacology (2019)
  3. Tandon PS, Sasser T, Gonzalez ES, Whitlock KB, Christakis DA, Stein MAPhysical Activity, Screen Time, and Sleep in Children With ADHDJournal of Physical Activity and Health. 2019, 16 (6), 416-422
  4. Sasser T, Schoenfelder E, Stein MATargeting functional impairments in the treatment of children and adolescents with ADHDCNS Drugs. 2017; 31: 97-107.
  5. Chronis-Tuscano A, Wang C, Strickland J, Almiral D, Stein MPersonalized treatment of mothers with ADHD and their young at-risk children: A SMART pilotJ Clin Child Adolesc Psychol. 2016; 45: 510-521.
  6. Chronis-Tuscano A, Wang CH, Woods KE, Strickland J, & Stein MAParent ADHD and evidence–based treatment for their children: Review and directions for future research. J Abnorm Child Psychol. 2017. 45: 501-517.
  7. Kim SJ, French WP, Shonka, S, Strickland J, & Stein MADose-response effects of long-acting liquid methylphenidate in children with attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): A Pilot Study. J Autism Dev Disord. 2017; 47: 2307-2313
  8. Snyder S, Rugino T, Hornig M, Stein MIntegration of an EEG biomarker with a clinician’s ADHD evaluationBrain Behav. 2015;5(4).
  9. Stein M, Waldman I, Newcorn J, Bishop J, Kittles R, Cook E. Dopamine Transporter Genotype and Stimulant Dose-Response in Youth with Attention-Deficit/Hyperactivity DisorderJournal of Child and Adolescent Psychopharmacology. 2014;24(5):238-244.
  10. Stein M, McGough J. The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder TherapyChild and Adolescent Psychiatric Clinics of North America. 2008;17(2):475-490.
  11. Arnett A, Stein M. Refining Treatment Choices for ADHDLancet Psychiatry. 2018 Sep;5(9):691-692. doi: 10.1016/S2215-0366(18)30295-5. Epub 2018

  12. Schulz KP, Bédard AV, Fan J, Hildebrandt TB, Stein MA, Ivanov I, Halperin JM, Newcorn JH. Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and AtomoxetineJ Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):602-609.e2. doi: 10.1016/j.jaac.2017.04.005. Epub 2017 May 10.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, email the Office of Science-Industry Partnerships